Kidney transplantationComplication: MetabolicOsteoporosis and Related Risk Factors in Renal Transplant Recipients
Section snippets
Materials and Methods
The study included 85 patients aged 17 to 50 years who had undergone renal transplantation 6 months to 2 years previously. Patients with a history of thyroid disease before or after transplantation were excluded. Baseline data included age, sex, height, and weight; duration of dialysis therapy before transplantation; days posttransplantation; immunosuppression regimen; cumulative dosages of prednisolone, cyclosporine, and mycophenolate mofetil (MMF) (CellCept; Roche Laboratories Inc, Lisle,
Results
Seventy-seven renal transplant recipients underwent BMD. Twenty-eight (36.4%) were women and 49 (63.6%) were men. Overall mean (SD; range) age was 34.68 (8.71; 17–51) years. Osteoporosis in the hip or spine regions was observed in 20 patients (26%). Hip BMD revealed normal findings in 16 patients (20.8%), osteopenia in 42 (54.5%), and osteoporosis in 19 (24.7%). Spine BMD revealed normal findings in 19 patients (24.7%), osteopenia in 52 (67.5%), and osteoporosis in 19 (24.7%). T test scores
Discussion
Osteoporosis was common in our patients. More than 90% of patients with osteoporosis had hip osteoporosis, which demonstrates the importance of diagnosis and initiation of treatment to reduce associated morbidity. Our patients were younger than 50 years, which may explain the prevalence of osteoporosis in a relatively young population and underscores the risk of fracture in subsequent years.
Cumulative dosage of cyclosporine was not predictive of bone loss in our study, although it has been
References (15)
- et al.
Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate
Am J Transplant
(2002) - et al.
Risk factors for osteoporosis in young renal transplant recipients
Transplant Proc
(2005) - et al.
Hospitalizations for fractures after renal transplantation in the United States
Ann Epidemiol
(2001) - et al.
The spectrum of long-term renal transplantation: Outcomes, complications, and clinical studies
Transplant Rev
(2002) - et al.
Osteoarticular pain and bone mineral density in renal transplantation
Transplant Proc
(2003) - et al.
High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation
J Am Soc Nephrol
(2000) - et al.
Prevalence of low trauma fractures in long-term kidney transplant patients with preserved renal function
Braz J Med Biol Res
(2006)
Cited by (25)
The correlation between sclerostin and bone mineral density in renal transplant recipients
2020, NefrologiaCitation Excerpt :The development of CKD-MBD is associated with increased morbidity-mortality and risk of bone fracture. Renal transplant recipients (RTRs) are at high risk of decreased bone mineral density (BMD) and CKD-MBD development due to the intense use of immunosuppressive drugs, presence of a previous bone lesion, and long term history of CKD.2 In the early posttransplant period, the risk of bone fracture is 7 times higher as compared to healthy individuals and 30% higher than patients with end-stage renal disease (ESRD).3
Behavior of Calcium, Phosphorus, and Parathormone Before Transplantation and in Months 1, 3, 6, 9, and 12 After Transplantation
2020, Transplantation ProceedingsCitation Excerpt :Calcium also normalized, but it was the least altered of the 3 values studied. Alis et al [1] demonstrated that osteoporosis occurred in 22% of cases after renal transplantation, something that we do not evaluate; however, this persistence of osteoporosis may possibly be related to our results rather than to a pre-existing condition. This should be evaluated in a more controlled study.
Evaluation of Bone Disease in Kidney Transplant Recipients
2017, Transplantation ProceedingsBone Disease and Serum Fibroblast Growth Factor-23 Levels in Renal Transplant Recipients
2016, Transplantation ProceedingsCitation Excerpt :In our KTrs, there was a relationship between BMD T scores in regard to the femur and age but not in regard to the lumbar spine. In some studies, no relationship was found between the type and duration of dialysis and the development of osteopenia/osteoporosis [14–17]. BMD was found to be decreased in dialysis patients in many studies [18–23].
Impact of tacrolimus on bone metabolism after kidney transplantation
2012, International ImmunopharmacologyCitation Excerpt :Thus, large randomized trials are necessary to determine the deleterious of TAC on bone in female recipients. We also found 27.78% of patients suffered bone loss in our study, far below the 90% reported by Ahmadpoor et al. [2], which can be explained by our young population (36.36 ± 8.18 years) and no postmenopausal women. However, posttransplant bone disease remains a common problem that may affect the patients' quality of life and must be of great concern, and more studies should be performed to investigate the optimal targeted therapeutic concentrations and achieve optimal balance between effective concentrations and toxic concentrations.
Official Positions for FRAX<sup>®</sup> Clinical Regarding Glucocorticoids: The impact of the Use of Glucocorticoids on the Estimate by FRAX<sup>®</sup> of the 10 Year Risk of Fracture. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX<sup>®M</sup>
2011, Journal of Clinical DensitometryCitation Excerpt :Although budesonide use in Crohn’s disease may be associated with less bone loss than other oral steroids, this is not true for all studies and it is not clear that there is a benefit in reducing fractures or whether fracture risk is increased (32,33). There are no studies to suggest that the use of high dose boluses of methylprednisolone or dexamethasone lead to increased fractures and studies measuring bone density or markers of bone turnover appear to show no or minimal impact on bone (34–37). Question: Should adrenal replacement effect on 10 year fracture risk be captured in FRAX?